

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/648,810	1	08/27/2003	Peng Cho Tang	034536-0406	3943
22428	7590	02/22/2005		EXAMINER	
FOLEY AN	JD LARI	ONER	WARD, PAUL V		
SUITE 500 3000 K STREET NW				ART UNIT	PAPER NUMBER
WASHINGTON, DC 20007			1623		
				DATE MAILED: 02/22/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/648,810	TANG ET AL.					
Office Action Summary	Examiner	Art Unit					
	PAUL V WARD	1623					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on	_•						
2a) ☐ This action is FINAL . 2b) ☑ This	action is non-final.						
•							
Disposition of Claims	•						
4)	vn from consideration. re rejected.						
Application Papers							
9)☐ The specification is objected to by the Examine	r.						
10)☐ The drawing(s) filed on is/are: a)☐ acce	☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the		·					
Replacement drawing sheet(s) including the correcting 11) The oath or declaration is objected to by the Ex		•					
Priority under 35 U.S.C. § 119							
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents 2. ☐ Certified copies of the priority documents 3. ☐ Copies of the certified copies of the priorical application from the International Bureau * See the attached detailed Office action for a list of the certified copies of the attached detailed Office action for a list of the certified copies of the certified copies of the priorical application from the International Bureau	s have been received. s have been received in Applicati ity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage					
Attachment(s)							
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	(PTO-413) ate						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		Patent Application (PTO-152)					

Application/Control Number: 10/648,810

Art Unit: 1623

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4, 10-15, 17-19, 21-22 and 24-29 are rejected under 35 U.S.C. 102(b) as being anticipated by Corbett et al. (WO 00/35909).

Applicant invention relates to indolinones compounds, which modulates the activity of protein kinases. Applicant claims 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds with a general formula I:

wherein all the variables are as defined in the claims.

Corbett teaches indolinones compounds to modulate protein kinases, which share the same formulaic compounds. (See formula I, Abstract). The compounds in the said patent has the same structure, which includes Het as an heteroaryl with at least 1 nitrogen, R^1 and R^2 as H, and Q as

(See pages 4-9, 15, and Examples 1-66).

Art Unit: 1623

The compounds in the published reference falls within the range of Applicants indolinones compounds. Since Corbett teaches the exact compounds, Applicant's claims are anticipated, and thus, rejected under 35 U.S.C. 102(b).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-4, 10-15, 17-19, 21-22 and 24-29 are under 35 U.S.C. 103(a) as being unpatentable over Corbett et al. (WO 00/35909).

Corbett teaches a generic group of aryloxindoles derivatives, which embraces Applicants' claimed compounds. (See formula 1, pages 4-15, Examples and definitions for Q, Het, R¹, and R²). The claims differ from the reference by reciting specific species and a more limited genus than the reference. However, it would have been obvious to one having ordinary skill in the art at the time of the invention to select any of the species of the genus taught by the reference, including those instantly claimed, because the skilled chemist would have the reasonable expectation that any of the species of the genus would have similar properties, and thus, the same use as taught for the genus as a whole. One of ordinary skill in the art would have been motivated to select the claimed compounds from the genus in the reference since such compounds would have been suggested by the reference as a whole. A prior art disclosed genus of useful

Application/Control Number: 10/648,810 Page 4

Art Unit: 1623

compounds is sufficient to render prima facie obvious a species falling within a genus.

Thus, Applicant's claims are obvious, and therefore, rejected under 35 U.S.C. 103.

Conclusion

Claims 1-4, 10-15, 17-19, 21-22 and 24-29 are pending. Claims 1-4, 10-15, 17-19, 21-22 and 24-29 are rejected. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is 571-272-2909. The examiner can normally be reached on M-F 8 am to 4 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

James O. Wilson

Supervisory Examiner,

Technology Center 1600